SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17th
March 11 2021 - 8:30AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the
“Company”), a late-stage clinical biopharmaceutical company focused
on developing novel cancer immunotherapies for a broad range of
indications, today announced that Angelos Stergiou, MD, ScD. h.c.,
President and Chief Executive Officer of SELLAS, will participate
in the Emerging Growth Virtual Conference hosted by M Vest LLC and
Maxim Group, LLC on Wednesday, March 17, 2021.
In addition to the SELLAS corporate presentation,
Dr. Stergiou will participate in the Cancer Vaccines Panel hosted
by Jason McCarthy, PhD, Maxim Senior Managing Director,
Biotechnology (Research Analyst) on Wednesday, March 17 at 1:00
p.m. ET. The panel will be an informative discussion on the market
opportunity for cancer vaccines as well as upcoming milestones from
the participating companies.
To attend, register here. An archived replay will
be available on SELLAS’ investor relations website at
www.sellaslifesciences.com/investors.
For more information about the conference, or to
schedule a one-on-one meeting with SELLAS management, please
contact your M Vest / Maxim representative directly, or KCSA
Strategic Communications at SELLAS@kcsa.com.
About SELLAS Life Sciences Group,
Inc. SELLAS is a late-stage clinical biopharmaceutical
company focused on developing novel cancer immunotherapeutics for a
broad range of indications. SELLAS’ lead product candidate,
galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering
Cancer Center and targets the WT1 protein, which is present in an
array of tumor types. GPS has potential both as a monotherapy and
in combination to address a broad spectrum of hematologic
malignancies and solid tumor indications. SELLAS’ second product
candidate, nelipepimut-S (NPS), is a HER2-directed cancer
immunotherapy with potential to treat patients with early-stage
breast cancer with low to intermediate HER2 expression, otherwise
known as HER2 1+ or 2+, which includes triple-negative breast
cancer patients, following the standard of care.
For more information on SELLAS, please
visit www.sellaslifesciences.com.
For more information, please
contact:
Investor Contacts Valter Pinto /
Allison Soss KCSA Strategic Communications Email: SELLAS@kcsa.com
Phone: 914.907.2675 / 215.272.2707
Media Contacts Caitlin Kasunich /
Raquel Cona KCSA Strategic Communications Email: SELLAS@kcsa.com
Phone: 212.896.1241 / 212.896.1276
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024